Results 251 to 260 of about 63,982 (290)
mRNA-engineered T cells against telomerase: a novel immunotherapy approach for cancer. [PDF]
EXCLI JMaqbool M +4 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Current Opinion in Oncology, 1997
Some of the most dramatic advances in the treatment of cancer have used the immune system in combination with conventional or transplantation chemotherapy. Adoptive immunotherapy has been used for relapses after allogeneic bone marrow transplantation, and it has been particularly effective for chronic myeloid leukemia.
K, Ballen, F M, Stewart
openaire +2 more sources
Some of the most dramatic advances in the treatment of cancer have used the immune system in combination with conventional or transplantation chemotherapy. Adoptive immunotherapy has been used for relapses after allogeneic bone marrow transplantation, and it has been particularly effective for chronic myeloid leukemia.
K, Ballen, F M, Stewart
openaire +2 more sources
Adoptive immunotherapy for cancer
Immunological Reviews, 2013SummaryRecent clinical success has underscored the potential for immunotherapy based on the adoptive cell transfer (ACT) of engineered T lymphocytes to mediate dramatic, potent, and durable clinical responses. This success has led to the broader evaluation of engineered T‐lymphocyte‐based adoptive cell therapy to treat a broad range of malignancies. In
Marco Ruella, Michael Kalos
openaire +2 more sources
Adoptive immunotherapy against sarcomas
Expert Opinion on Biological Therapy, 2014Conventional treatments reached an unsatisfactory therapeutic plateau in the treatment of advanced unresectable bone and soft tissue sarcomas that remain an unsolved medical need. Several evidences support the concept that adoptive immunotherapy may effectively integrate within the complex and multidisciplinary treatment of sarcomas.In this work we ...
MESIANO, GIULIA +11 more
openaire +3 more sources
Regulation of adoptive immunotherapy.
[Rinsho ketsueki] The Japanese journal of clinical hematology, 2016Adoptive immunotherapy using chimeric antigen receptor (CAR)-modified T cells has provided a major breakthrough in the treatment of hematological malignancies. In Japan, it is expected that CD19 CAR-T cell therapy will be introduced earlier in clinical B cell malignancy settings and/or that a novel CAR-T cell therapy will be developed for non-B cell ...
Nobuhiro Nishio +2 more
openaire +3 more sources
Chemo-immunotherapy and chemo-adoptive immunotherapy of cancer
Cancer Treatment Reviews, 2001The chemo-immunotherapy (CIT) and chemo-adoptive immunotherapy (CAIT) regimens tested in the past decade are summarized. From them we have learned a great deal about the interactions between various chemotherapeutic agents, immune modulating agents and effector cells.
R.B Hutchison, G.G Gomez, C.A Kruse
openaire +2 more sources
Adoptive Immunotherapy for Malignant Glioma
The Cancer Journal, 2003Despite remarkable advancements in imaging modalities and treatment options available to patients diagnosed with malignant brain tumors, the prognosis for those with high-grade lesions remains poor. The imprecise mechanisms of currently available treatments to manage these tumors do not spare damage to the normal surrounding brain and often result in ...
John H. Sampson +2 more
openaire +3 more sources
Adoptive Immunotherapy in Chimeras [PDF]
, 2003 Depletion of T-cells from the marrow by treatment with absorbed antithymocyte globulin (ATG) prevents GVHD in DLA-identical littermates and transfusion of donor lymphocytes on days 1 and 2, 21 and 22 induces fatal GVHD. However transfusion on days 61 and 62 dose not produce GVHD and the animals survive.
Martin Weber +9 more
openaire +1 more source
Adoptive Immunotherapy for Hodgkin's Lymphoma
International Journal of Hematology, 2006Adoptive transfer of tumor-specific T-cells is an attractive strategy for the treatment of patients with refractory or relapsed Hodgkin's lymphoma. However, Hodgkin's lymphomas possess a range of tumor-evasion mechanisms, which must be overcome before the full potential of immunotherapies can be achieved.
Catherine M. Bollard +2 more
openaire +3 more sources
Adoptive immunotherapy of urologic tumors
1989The treatment of humans with advanced cancer represents a major therapeutic challenge. One approach to treating metastatic cancer is immunotherapy, which can be classified into active and passive categories. Active immunotherapy refers to the immunization of the tumor-bearing host with materials that attempt to induce in the host a state of immune ...
Steven A. Rosenberg, Arie S. Belldegrun
openaire +3 more sources